ROYAL COLLEGE OF PODIATRY

>

>

Medicines recall issued for ChloraPrep applicators

Medicines recall issued for ChloraPrep applicators

Healthcare professionals are being advised that batches of ChloraPrep 2% applicators with an expiry date up to and including May 2029 are being recalled due to a potential sterility issue affecting the packaging process.

What's happened 

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 2 Medicines Recall for batches of ChloraPrep 2% 1mL applicators with an expiry date up to and including May 2029 manufactured by Becton Dickinson UK Ltd. 

This follows an earlier MHRA recall, which The New Podiatrist reported in June, relating to specific batches of ChloraPrep products. The latest recall expands the action to include all affected batches with an expiry date up to and including May 2029. 

The recall follows concerns about a potential breach of sterility during the packaging process. 

ChloraPrep products are commonly used to disinfect the skin before invasive procedures, including injections and minor surgical procedures. 

Healthcare providers are advised to stop supplying the affected batches. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process. 

Why this matters to members 

Some podiatrists may use ChloraPrep products when preparing skin before administering local anaesthetic injections or carrying out other clinical procedures. 

Members should review the recall notice, check stock held within their service or practice and ensure any affected products are removed from use. 

What happens next 

Further information, including affected batch numbers and actions required, is available in the MHRA recall notice. 

Links and references 

Featured Posts

Related Post

Jul 14, 2026

Post by

Rafael Nadal was one of the most successful tennis players of his generation. At age 19, however, his career was seriously threatened by chronic midfoot pain. He chose to play on, adopting a highly unconventional – and potentially controversial – approach to pain management.

Jul 9, 2026

Post by

The Royal College of Podiatry has issued a position statement on the use of injectable hyaluronic acid-based dermal hydrogels in the foot. While these treatments are attracting growing interest, the College says that patient safety, prescribing compliance and strong clinical governance must remain the priority.

Jul 1, 2026

Post by

Healthcare professionals are being advised that certain packs of Flucloxacillin Capsules BP 500mg contain the wrong patient information leaflet (PIL).

Lower limb immobilisation presents clinicians with a widespread but tough question – when does the risk of venous thromboembolism outweigh the risks associated with anticoagulation? Emerging evidence is helping to determine decision-making, but uncertainty remains.

Podiatrists say audit matters. But a new survey suggests restrictions in time, systems and standardisation are holding the profession back from building a national picture of outcomes.

May 1, 2026

Post by

A new national campaign and not-for-profit footwear hub aim to address concerns about children wearing poorly fitting shoes, offering parents practical guidance on footwear choices.

Jul 14, 2026

Post by

Rafael Nadal was one of the most successful tennis players of his generation. At age 19, however, his career was seriously threatened by chronic midfoot pain. He chose to play on, adopting a highly unconventional – and potentially controversial – approach to pain management.

Jul 9, 2026

Post by

The Royal College of Podiatry has issued a position statement on the use of injectable hyaluronic acid-based dermal hydrogels in the foot. While these treatments are attracting growing interest, the College says that patient safety, prescribing compliance and strong clinical governance must remain the priority.

Jul 1, 2026

Post by

Healthcare professionals are being advised that certain packs of Flucloxacillin Capsules BP 500mg contain the wrong patient information leaflet (PIL).

Lower limb immobilisation presents clinicians with a widespread but tough question – when does the risk of venous thromboembolism outweigh the risks associated with anticoagulation? Emerging evidence is helping to determine decision-making, but uncertainty remains.

RCPod Annual Conference

Podiatry 2026

Podiatry 2026

Podiatry 2026

Two events, three days of high-impact CPD — our reimagined annual conference and exhibition, plus the RCPod Learning Academy Immersive Day.

Two events, three days of high-impact CPD — our reimagined annual conference and exhibition, plus the RCPod Learning Academy Immersive Day.

26–28 November

ICC Birmingham

Your place

26–28

Nov 2026

ICC Birmingham

Conference & Exhibition + Immersive Day

Early bird closes 31 Aug

Book your place

Member, concession & non-member rates available.